This prospective, multicenter cohort study sponsored by Shanghai General Hospital aims to evaluate the impact of donor characteristics (parous female vs. young male) on GVHD prophylaxis outcomes in high-risk acute myeloid leukemia (AML) patients undergoing haplo-HSCT. The study targets a niche yet critical segment of the hematologic oncology market, particularly focusing on high-risk AML patients who have limited treatment options. The findings could influence clinical practices and donor selection criteria, potentially leading to improved patient outcomes and market positioning for therapies that enhance transplantation success rates. Given the increasing prevalence of AML and the demand for effective GVHD prophylaxis, successful outcomes may enhance the competitive landscape for related therapies and donor management strategies.